RESEARCH PROTOCOL GUIDES

OVERVIEW

5-Amino-1MQ blocks the NNMT enzyme and is studied for its role in metabolism, NAD+ regulation, cellular energy and body composition.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 0.5 mg to 5 mg
• Frequency: Daily
• 1 mg to 2 mg is a good dose to start.

CYCLE

• Duration: 16 weeks on
• Break: 4 weeks off

KEY NOTES

• Preferably administered first thing in the morning alongside NAD+ and MOTS-C, as some users report increased energy levels.

OVERVIEW

ARA-290 is studied for neuropathy, inflammation and tissue protection. Research explores its potential effects on chronic pain and sensitivity associated with small-fibre neuropathy, cell-survival pathways, programmed cell death (apoptosis), and pro-inflammatory cytokines.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 1–4 mg
• Frequency: Daily, or two days off per week.

CYCLE

• Duration: 4–12 weeks on.
• Break: 4–8 weeks off between cycles.

KEY NOTES

• Find your most comfortable dose and stay on it.
• Administered in the morning, but the schedule can be flexible.

OVERVIEW

A peptide studied for its role in tendon, ligament, muscle, gut and tissue-repair processes.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 0.25 mg to 1 mg
• Frequency: 1–2 times daily
• If treating an injury, 1 mg daily until the injury is healed.

CYCLE

• Duration: 4–12 weeks on
• Break: 2–4 weeks off

KEY NOTES

• Administered either morning or evening, or both.
• Evening is best if using one administration only.

OVERVIEW

An amylin receptor agonist studied for appetite control, increased fullness and weight management. Helps regulate food intake and slow gastric emptying, and is often paired with GLP-1 protocols to support appetite suppression and satiety.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 0.3 mg to 4.5 mg
• Frequency: Weekly
• Start at the lowest dose and stay on it. Only increase if needed.

CYCLE

• Duration: 4–12 weeks on
• Break: 4–8 weeks off

KEY NOTES

• Administered 3–4 days after the GLP-1 shot to support appetite suppression while using a GLP-1.

OVERVIEW

CARTALAX is a cartilage and connective-tissue peptide bioregulator. Proposed mechanisms include effects on gene regulation, structural proteins and cell-survival pathways. Claims concerning cardiac remodelling and tissue protection remain unverified.

RECONSTITUTION

RESEARCH PROTOCOL

CYCLE

• Duration: 8–12 weeks on.
• Break: 8–12 weeks off between cycles.

KEY NOTES

• Administered first thing in the morning, but timing can be flexible.
• Maintain a consistent schedule.
• Often paired with BPC-157 and TB-500—the Wolverine Stack—a combination informally known as the “Deadpool Stack.”

OVERVIEW

A blend that stimulates growth-hormone release, studied for fat metabolism, lean muscle development and recovery. Also studied for improved sleep quality, skin elasticity and recovery from physical exertion or injury.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 200 mcg to 600 mcg
• Frequency: Daily
• Gradually titrate up once comfortable.

CYCLE

• Duration: 3–6 months on
• Break: 4–8 weeks off

KEY NOTES

• Administered before bed after fasting for 2–3 hours to align with the body’s natural growth-hormone pulses.

OVERVIEW

A copper-binding peptide studied for skin renewal, collagen and elastin production, and tissue repair. Supports skin firmness, reduced appearance of fine lines, and scalp and hair-follicle health.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 1 mg to 5 mg
• Frequency: Daily
• 2 mg to 2.5 mg is a good dose to stay at.

CYCLE

• Duration: 4–12 weeks on
• Break: 4–8 weeks off

KEY NOTES

• Administered before bed to maximize cellular repair and regeneration.

OVERVIEW

The body’s master antioxidant, supporting cellular defence, detoxification and protection against oxidative stress. Also studied for skin brightening, a more even skin tone and reduced hyperpigmentation.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 200 mg to 400 mg
• Frequency: 3–4 times weekly
• Maintain a limit of 1200 mg per week.

CYCLE

• Does not need to be cycled.
• If cycling: 8–12 months on, followed by 4–8 weeks off.

KEY NOTES

• Administered before bed to maximize detoxification and antioxidant benefits.

OVERVIEW

A hormone-signalling peptide studied for its role in fertility, reproductive health and hormonal balance. Supports signalling involved in reproductive-hormone release, menstrual-cycle regulation and ovulation.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 50 mcg to 200 mcg
• Frequency: 1–2 times daily
• Stay at a low dose if possible and pay attention to bloodwork.

CYCLE

• Duration: 4–12 weeks on
• Break: 2–8 weeks off

KEY NOTES

• Administered in the morning immediately after waking to signal the pituitary gland during its most responsive window.

OVERVIEW

A blend of KPV, GHK-Cu, BPC-157 and TB-500 studied for gut health, tissue repair and recovery. Combines properties involved in inflammation regulation, collagen and elastin production, skin renewal and wound healing.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 4 mg total blend Contains 2.5 mg GHK-Cu, 0.5 mg KPV, 0.5 mg BPC-157 and 0.5 mg TB-500.
• Frequency: Daily

CYCLE

• Duration: 4–12 weeks on
• Break: 4–8 weeks off

KEY NOTES

• Administered at night or before bed to support tissue repair and regeneration.

OVERVIEW

A tripeptide studied for gut health, inflammation regulation and tissue repair. Also studied for intestinal-lining support and reducing redness, itching and swelling associated with inflammatory skin conditions.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 0.25 mg to 1 mg
• Frequency: Daily
• Most beneficial at 0.5 mg, but can go up to 1 mg if needed.

CYCLE

• Duration: 8–12 weeks on
• Break: 4–8 weeks off

KEY NOTES

• Administered before bed to maximize anti-inflammatory and gut-repair benefits.

OVERVIEW

A mitochondrial-derived peptide studied for metabolic function, energy production and endurance. Activates the AMPK pathway and is studied for its exercise-mimetic effects and role in mitochondrial function.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 1 mg to 5 mg
• Frequency: 2–3 times weekly
• 1 mg to 2 mg is a good dose to stay at.

CYCLE

• Duration: 8–12 weeks on
• Break: 4–8 weeks off

KEY NOTES

• Administered first thing in the morning while fasted.
• Continue fasting for 2–4 hours after administration.
• Best utilised on days involving workouts or physical activity.

OVERVIEW

A tanning peptide studied for melanin production and skin pigmentation. Its activity is more focused on the MC1 receptor, with less prominent appetite and sexual effects than MT-2.

RECONSTITUTION

RESEARCH PROTOCOL

Fair skin — Fitzpatrick I–II

Medium to olive skin — Fitzpatrick III–IV

CYCLE

• Initial phase: 8 weeks, followed by maintenance

KEY NOTES

• Can be administered in the morning.
• Fasting is not essential.
• Food does not appear to change absorption.
• Gradual pigmentation develops over several weeks.

OVERVIEW

A tanning peptide studied for melanin production and skin pigmentation, with broader melanocortin receptor activity than MT-1. It can also affect appetite and sexual arousal.

RECONSTITUTION

RESEARCH PROTOCOL

CYCLE

• Loading duration: 1–2 weeks, followed by maintenance

KEY NOTES

• Evening administration is used to sleep through potential nausea.
• Food does not appear to change absorption.
• If transitioning to MT-1, finish the loading phase, wait 5–7 days, then start MT-1 for longer-term maintenance.

OVERVIEW

A coenzyme involved in cellular energy production, DNA repair and metabolic health. Supports the conversion of nutrients into energy and redox reactions involved in mitochondrial, brain and organ function.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 25 mg to 100 mg
• Frequency: Daily or 3 times weekly
• 25 mg to 50 mg is a good dose to stay at.

CYCLE

• Does not need to be cycled.

KEY NOTES

• Administered first thing in the morning.
• Lower the dose slightly when paired with 5-Amino-1MQ.

OVERVIEW

A peptide studied for sexual desire, arousal and sexual response. Works through pathways in the brain, rather than focusing on blood flow.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 0.5 mg to 2 mg
• Frequency: As needed
• Start low and assess the reaction, working up to a maximum of 2 mg.
• Do not use twice within 24 hours.

CYCLE

• Duration: 2–8 weeks on
• Break: 1–2 weeks off

KEY NOTES

• Administered 30–60 minutes before the activity.

OVERVIEW

A triple-receptor agonist studied for appetite regulation, metabolic function and weight management. Acts on GLP-1, GIP and glucagon receptors, supporting appetite control alongside energy metabolism.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 2 mg to 10 mg
• Frequency: Weekly
• Titration steps: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg
• Titrate every 4 weeks and assess response.

CYCLE

• Does not need to be cycled.

KEY NOTES

• Avoid fatty foods on the day of administration to minimise side effects.
• Appetite suppression may feel less pronounced than with tirzepatide because of the added glucagon agonism.

OVERVIEW

A peptide studied for mitochondrial function, cellular energy and protection against oxidative stress. Binds to cardiolipin in the inner mitochondrial membrane, supporting mitochondrial structure and function while helping reduce reactive oxygen species.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 2 mg to 5 mg
• Frequency: Daily

CYCLE

• Duration: 8–12 weeks on
• Break: 4–8 weeks off

KEY NOTES

• Administered before bed for the first cycle. Otherwise, administered first thing in the morning.
• Typically cycled before MOTS-C or NAD+ to support mitochondrial health ahead of those protocols.
• Typically cycled once or twice a year.

OVERVIEW

A GHRH analogue studied for growth-hormone release, body composition and visceral-fat reduction. Also studied for improvements in lipid profiles and triglyceride levels associated with metabolic stress.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 0.5 mg to 2 mg
• Frequency: Daily
• 1 mg is a good dose to stay at.

CYCLE

• Duration: 8–12 weeks on
• Break: 4–8 weeks off

KEY NOTES

• Administered after fasting for 2–3 hours, 30 minutes before bed.

OVERVIEW

A dual-receptor agonist studied for appetite regulation, blood-glucose control and weight management. Acts on GLP-1 and GIP receptors to support appetite suppression and reduced food intake.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 2.5 mg to 15 mg
• Frequency: Weekly
• Titration steps: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
• Titrate every 4 weeks and assess response.

CYCLE

• Does not need to be cycled.

KEY NOTES

• Avoid fatty foods on the day of administration to minimise side effects.

OVERVIEW

A blend of BPC-157 and TB-500 studied for tissue repair and injury recovery. Combines properties involved in tendon, ligament and muscle repair, cellular migration and inflammation regulation.

RECONSTITUTION

RESEARCH PROTOCOL

• Dose: 250 mcg to 500 mcg
• Frequency: 1–2 times daily

CYCLE

• Duration: 4–12 weeks on
• Break: 2–4 weeks off

KEY NOTES

• Administered either morning or evening, or both.
• Evening is best if using one administration only.